{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-103622","form_type":"8-K","ticker":"MIRM","cik":"0001759425","company_name":"Mirum Pharmaceuticals, Inc.","filed_at":"2023-04-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.419671+00:00","generated_at":"2026-06-17T01:26:39.595824+00:00","sec_items":["1.01","1.02","2.03","3.02","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Mirum prices $316.25M 4.00% convertible notes due 2029; repurchases $192.7M revenue interests","bullets":["Issued $316.25M principal (incl. full exercise of $41.25M over-allotment) of 4.00% convertible senior notes due May 1, 2029.","Initial conversion price ~$31.74/share, a 35% premium over $23.51 closing stock price on April 12, 2023.","Net proceeds ~$305.4M; used ~$192.7M to repurchase revenue interests from Oberland Capital (RIPA) and terminate that agreement.","Remaining proceeds expected for general corporate purposes, including working capital and potential acquisitions.","Notes are senior unsecured; callable by Mirum after May 5, 2026 if stock price >130% of conversion price."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-103622","json":"https://secwatch.observer/filing/0001193125-23-103622.json","markdown":"https://secwatch.observer/filing/0001193125-23-103622.md","text":"https://secwatch.observer/filing/0001193125-23-103622.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1759425/000119312523103622/0001193125-23-103622-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1759425/000119312523103622/d487416d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T01:26:39.595824+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"df964cb951a270d53293358c93465cf1b09d076b","claim":"Mirum Pharmaceuticals, Inc. incurred convertible notes of $316.25 million at 4.00% per annum maturing May 1, 2029.","evidence_excerpt":"On April 17, 2023, Mirum Pharmaceuticals, Inc. (the “Company”) issued $316.25 million principal amount of its 4.00% Convertible Senior Notes due 2029","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1759425/000119312523103622/0001193125-23-103622-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"$316.25 million"},{"label":"Rate","value":"4.00% per annum"},{"label":"Maturity","value":"May 1, 2029"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"15d5dd54b0b4bdaf7308a4a5d80076aba9434ef4","claim":"Mirum Pharmaceuticals, Inc. entered into Indenture with U.S. Bank Trust Company, National Association, as trustee valued at $316.25 million principal amount of its 4.00% Convertible Senior Notes due 2029 (effective 2023-04-17).","evidence_excerpt":"On April 17, 2023, Mirum Pharmaceuticals, Inc. (the “Company”) issued $316.25 million principal amount of its 4.00% Convertible Senior Notes due 2029 (the “Notes”). The Notes were issued pursuant to, and are governed by, an indenture (the “Indenture”), dated as of April 17, 2023, between the Company and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1759425/000119312523103622/0001193125-23-103622-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"notes offering"},{"label":"Counterparty","value":"U.S. Bank Trust Company, National Association, as trustee"},{"label":"Value","value":"$316.25 million principal amount of its 4.00% Convertible Senior Notes due 2029"},{"label":"Effective","value":"2023-04-17"}],"fact_type":"material_agreement"},{"claim_id":"f296c2e4d486491d6618fe83dc5eb4cfccf2a0c2","claim":"Mirum Pharmaceuticals, Inc. entered into Purchase Agreement with the initial purchasers of the Notes valued at $41.25 million principal amount of Notes.","evidence_excerpt":"Pursuant to the purchase agreement among the Company and the initial purchasers of the Notes (the “Purchase Agreement”), the Company granted the initial purchasers an option to purchase, for settlement within a period of 13 days from, and including, the date the Notes are first issued, up to an additional $41.25 million principal amount of Notes.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1759425/000119312523103622/0001193125-23-103622-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"the initial purchasers of the Notes"},{"label":"Value","value":"$41.25 million principal amount of Notes"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}